MX2024013116A - Forma solida de tartrato 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol - Google Patents
Forma solida de tartrato 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-olInfo
- Publication number
- MX2024013116A MX2024013116A MX2024013116A MX2024013116A MX2024013116A MX 2024013116 A MX2024013116 A MX 2024013116A MX 2024013116 A MX2024013116 A MX 2024013116A MX 2024013116 A MX2024013116 A MX 2024013116A MX 2024013116 A MX2024013116 A MX 2024013116A
- Authority
- MX
- Mexico
- Prior art keywords
- tartrate
- difluoropropan
- fluoropropyl
- azetidin
- pyrido
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22170407 | 2022-04-28 | ||
| PCT/EP2023/061060 WO2023209062A1 (en) | 2022-04-28 | 2023-04-27 | Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024013116A true MX2024013116A (es) | 2024-11-08 |
Family
ID=81392840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013116A MX2024013116A (es) | 2022-04-28 | 2024-10-24 | Forma solida de tartrato 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250282775A1 (https=) |
| EP (1) | EP4514792A1 (https=) |
| JP (1) | JP2025512583A (https=) |
| KR (1) | KR20250006222A (https=) |
| CN (1) | CN119156386A (https=) |
| AU (1) | AU2023262166A1 (https=) |
| CA (1) | CA3255956A1 (https=) |
| IL (1) | IL316096A (https=) |
| MX (1) | MX2024013116A (https=) |
| TW (1) | TW202400141A (https=) |
| WO (1) | WO2023209062A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202602868A (zh) * | 2024-04-15 | 2026-01-16 | 瑞士商諾華公司 | 瑞波西利的藥物組成物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI874834B (zh) | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| CR20200621A (es) | 2018-06-21 | 2021-02-03 | Hoffmann La Roche | Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso |
-
2023
- 2023-04-27 AU AU2023262166A patent/AU2023262166A1/en active Pending
- 2023-04-27 CA CA3255956A patent/CA3255956A1/en active Pending
- 2023-04-27 TW TW112115780A patent/TW202400141A/zh unknown
- 2023-04-27 IL IL316096A patent/IL316096A/en unknown
- 2023-04-27 WO PCT/EP2023/061060 patent/WO2023209062A1/en not_active Ceased
- 2023-04-27 JP JP2024562812A patent/JP2025512583A/ja active Pending
- 2023-04-27 CN CN202380036684.8A patent/CN119156386A/zh active Pending
- 2023-04-27 KR KR1020247039066A patent/KR20250006222A/ko active Pending
- 2023-04-27 US US18/859,397 patent/US20250282775A1/en active Pending
- 2023-04-27 EP EP23722867.1A patent/EP4514792A1/en active Pending
-
2024
- 2024-10-24 MX MX2024013116A patent/MX2024013116A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023209062A1 (en) | 2023-11-02 |
| CN119156386A (zh) | 2024-12-17 |
| JP2025512583A (ja) | 2025-04-17 |
| KR20250006222A (ko) | 2025-01-10 |
| IL316096A (en) | 2024-12-01 |
| AU2023262166A1 (en) | 2024-10-17 |
| US20250282775A1 (en) | 2025-09-11 |
| TW202400141A (zh) | 2024-01-01 |
| EP4514792A1 (en) | 2025-03-05 |
| CA3255956A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211207A1 (es) | Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1- (3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| AR116052A2 (es) | Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol | |
| SV2010003706A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas | |
| MX373230B (es) | Composición farmacéutica y su administración. | |
| BRPI0818161B8 (pt) | mistura estável compreendendo agonista de receptores de s1p, sua forma de dosagem final e seu uso | |
| NZ593295A (en) | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| UY36665A (es) | Derivados de ciclohexano sustituidos con amidas | |
| MX2024013116A (es) | Forma solida de tartrato 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| MX2009005909A (es) | Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)eti l]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol. | |
| CL2019003324A1 (es) | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) | |
| EP4454703A3 (en) | Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same | |
| CL2013002810A1 (es) | Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple. | |
| CY1118976T1 (el) | Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης | |
| MX2021015853A (es) | Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida. | |
| SA517390552B1 (ar) | مركبات بلورية مثبط امتصاص ثلاثي غير متوازن | |
| WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
| BR112023025757A2 (pt) | Formas sólidas de um composto de fórmula, composição farmacêutica, uso de forma sólida, método para tratamento terapêutico, processos para a preparação de um composto de fórmula e para a preparação de forma a polimórfica cristalina de um composto de fórmula e invenção | |
| CL2012000097A1 (es) | Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros. | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| ECSP099596A (es) | Composición farmacéutica que contiene una combinación de tramadol y ketoprofeno | |
| CO2017005640A2 (es) | Fragancia precursora de 3-(4-isobutil-2-metilfenil)propanal y composiciones de la misma | |
| AR086818A1 (es) | Forma cristalina b de la 2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida |